Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House anticounterfeiting bill prohibits altering of drug, dietary supplement ID codes.

This article was originally published in The Tan Sheet

Executive Summary

HOUSE ANTICOUNTERFEITING BILL: PRODUCT ID CODE ALTERING PROHIBITED for a variety of consumer products, including dietary supplements and pharmaceuticals, under Rep. Bob Goodlatte's (R- Va.) Trademark Anticounterfeiting Act. HR 3891 would amend the Lanham Act to make it unlawful for anyone other than the consumer or manufacturer of a product to "directly or indirectly alter, conceal, remove, obliterate, deface, strip or peel any product identification code affixed to or embedded in" that product. HR 3891 was introduced by Goodlatte May 19 and passed by the House Judiciary Committee by voice vote July 16. Floor debate has not been scheduled.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel